Ercolani Cristiana, Di Benedetto Anna, Bonomo Claudia, Visca Paolo, Palange Aldo, Assisi Daniela, Forcella Daniele, Terrenato Irene, Pescarmona Edoardo, Ciliberto Gennaro, Cecere Fabiana Letizia, Cappuzzo Federico, Buglioni Simonetta
Pathology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Department of Digestive Endoscopy, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
J Clin Pathol. 2022 Dec;75(12):844-850. doi: 10.1136/jclinpath-2021-207726. Epub 2021 Aug 16.
The minimally invasive procedures used in the diagnostic workup of patients with advanced non-small cell lung cancer (NSCLC) often provide poor yields of pathological material suitable for molecular analyses. Not infrequently, the DNA yield from small biopsies/cytological samples is insufficient for the assessment of genomic biomarkers that inform personalised therapies. The Idylla mutation test (IEMT) has been specifically designed to process formalin-fixed paraffin-embedded sections without requiring preliminary DNA extraction.This study aims to evaluate the diagnostic accuracy of IEMT when used to analyse archival histopathology material. More specifically, our objective was to establish whether or not different staining procedures could affect assay performance.
Twenty NSCLC samples were selected accordingly to mutational status. To mimic archived stained material, sections were subjected to H&E staining, fluorescent in situ hybridisation analyses or immunodetection by immunohistochemistry before being processed for IEMT.
Parallel assessment of mutational status by IEMT on stained sections and next-generation sequencing on DNA yielded a concordant result in 50 out of 60 tests (83.3%). The discoloration of H&E of the archived sample was found to be the optimal procedure to highlight all the actionable alterations of .
IEMT can provide remarkable diagnostic accuracy for the assessment of mutational status also when the only source of pathological material available for molecular analyses is represented by H&E stained sections. Ad hoc supervision by a qualified molecular biologist is in any case recommended.
用于晚期非小细胞肺癌(NSCLC)患者诊断检查的微创程序,通常提供的适合分子分析的病理材料产量较低。小活检/细胞学样本的DNA产量常常不足以评估指导个性化治疗的基因组生物标志物。Idylla突变检测(IEMT)专门设计用于处理福尔马林固定石蜡包埋切片,无需预先提取DNA。本研究旨在评估IEMT用于分析存档组织病理学材料时的诊断准确性。更具体地说,我们的目标是确定不同的染色程序是否会影响检测性能。
根据突变状态选择20个NSCLC样本。为模拟存档的染色材料,在进行IEMT处理之前,先对切片进行苏木精-伊红(H&E)染色、荧光原位杂交分析或免疫组化免疫检测。
IEMT对染色切片的突变状态与DNA的二代测序进行平行评估,60次检测中有50次(83.3%)结果一致。发现存档样本的H&E褪色是突出所有可操作改变的最佳程序。
当可用于分子分析的病理材料唯一来源是H&E染色切片时,IEMT在评估突变状态方面也可提供显著的诊断准确性。无论如何,建议由合格的分子生物学家进行专门监督。